Collegium Pharmaceutical (COLL) Amortization of Deferred Charges (2018 - 2026)
Collegium Pharmaceutical has reported Amortization of Deferred Charges over the past 7 years, most recently at $1.3 million for Q4 2025.
- For Q4 2025, Amortization of Deferred Charges fell 10.39% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $4.8 million, down 11.89%, while the annual FY2025 figure was $5.3 million, 11.22% down from the prior year.
- Amortization of Deferred Charges for Q4 2025 was $1.3 million at Collegium Pharmaceutical, up from $1.1 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $2.5 million in Q2 2022 and troughed at $779000.0 in Q4 2021.
- A 5-year average of $1.5 million and a median of $1.3 million in 2024 define the central range for Amortization of Deferred Charges.
- Biggest five-year swings in Amortization of Deferred Charges: plummeted 69.39% in 2021 and later skyrocketed 205.91% in 2022.
- Year by year, Amortization of Deferred Charges stood at $779000.0 in 2021, then skyrocketed by 205.91% to $2.4 million in 2022, then fell by 17.62% to $2.0 million in 2023, then dropped by 27.46% to $1.4 million in 2024, then dropped by 10.39% to $1.3 million in 2025.
- Business Quant data shows Amortization of Deferred Charges for COLL at $1.3 million in Q4 2025, $1.1 million in Q3 2025, and $1.1 million in Q2 2025.